Andreas Halvorsen's hedge fund firm Viking Global has filed a 13D with the SEC regarding shares of Urovant Sciences (UROV). Per the filing, Viking now shows a 75.6% stake in the company with over 22.7 million shares, though the 13D notes that "The Reporting Persons do not directly own any Common Shares."
The company recently completed its initial public offering (IPO). Viking has previously invested in Roivant Sciences in 2016, a holding company that has created numerous subsidiaries, including newly public Urovant, which could explain Viking's SEC filing. Other Roivant subsidiaries include Axovant Sciences, Myovant Sciences, and Enzyvant Sciences, to name a few.
Viking also invested in Roivant again in 2017 with an undisclosed amount of funding. SoftBank's Vision Fund is also an investor in Roivant, but not the subsidiaries, at least that was the case as of mid-2017. Roivant was founded by Vivek Ramaswamy.
Friday, October 12, 2018
Viking Global Files 13D on Urovant Sciences
Monday, February 13, 2017
Viking Global Discloses Myovant Sciences Position
Andreas Halvorsen's hedge fund firm Viking Global has filed a 13G with the SEC regarding shares of Myovant Sciences (MYOV). Per the filing, Viking now owns 61.8% of the company with over 37.23 million shares.
This is a newly disclosed public equity position for the firm and the filing was made due to activity on December 31st. However, Viking previously invested in private company Roivant Sciences. Roivant has stakes in numerous other biopharma companies that have been spun-out, including Myovant.
Myovant completed its initial public offering in the latter months of 2016.
Per Google Finance, Myovant Sciences is ".a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction."
